Company: SHPH
Filing Date: 2025-01-24
Form Type: 424B3
Source: 0001493152-25-003508
Chunk: 194

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-01-24
Form: 424B3
Chunk 194
---
 20 |   |     |               |          17 |   |
| Additional paid in capital, as restated                                                                                                           |     |               |  29,489,055 |   |     |               |  26,518,433 |   |
| Accumulated deficit, as restated                                                                                                                  |     |               | (25,433,304 | ) |     |               | (18,840,581 | ) |
| Total Stockholders’ Equity                                                                                                                        |     |               |   4,055,771 |   |     |               |   7,677,869 |   |
| Total Liabilities and Stockholders’ Equity                                                                                                        |     | $             |   5,951,736 |   |     | $             |   8,653,545 |   |

<div align='center'>The accompanying notes are an integral part of these consolidated financial statements.</div>

| F-22 |

<div align='center'>Shuttle Pharmaceuticals Holdings, Inc.

Consolidated Statements of Operations</div>

|                                                                                                               |     | 2023                    
 Year Ended December 31, 
 2023                    |            |   |     | 2022         
 2022         |            |   |
|:--------------------------------------------------------------------------------------------------------------|:----|:------------------------|-----------:|:--|:----|:-------------|-----------:|:--|
|                                                                                                               |     |                         |            |   |     | -as restated |            |   |
| Revenue                                                                                                       |     | $                       |          — |   |     |              |          — |   |
| Operating expenses                                                                                            |     |                         |            |   |     |              |            |   |
| Research and development, net of contract expense reimbursements, as restated                                 |     |                         |  3,517,093 |   |     |              |  1,047,385 |   |
| Research and development                                                                                      |     |                         |  3,517,093 |   |     |              |  1,047,385 |   |
| General and administrative, as restated                                                                       |     |                         |  1,046,854 |   |     |              |    473,714 |   |
| General and administrative                                                                                    |     |                         |  1,046,854 |   |     |              |    473,714 |   |
| Legal and professional, as restated